Is there room for non-dopaminergic treatment in Parkinson disease?

Abraham Lieberman, Narayanan Krishnamurthi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

Original languageEnglish (US)
Pages (from-to)347-348
Number of pages2
JournalJournal of Neural Transmission
Volume120
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Parkinson Disease
Pharmaceutical Preparations
Paranoid Disorders
Orthostatic Hypotension
Hallucinations
Gait
Freezing
Drug-Induced Dyskinesia
Droxidopa
Dopamine Agents
Serotonin Receptors
Dyskinesias
Levodopa
Cholinergic Agents
Norepinephrine

Keywords

  • Levodopa
  • Non-dopaminergic drugs
  • Non-motor symptoms
  • Parkinson disease

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Is there room for non-dopaminergic treatment in Parkinson disease? / Lieberman, Abraham; Krishnamurthi, Narayanan.

In: Journal of Neural Transmission, Vol. 120, No. 2, 02.2013, p. 347-348.

Research output: Contribution to journalArticle

@article{3fd3b48e0f054173bd136fc05184fee1,
title = "Is there room for non-dopaminergic treatment in Parkinson disease?",
abstract = "Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.",
keywords = "Levodopa, Non-dopaminergic drugs, Non-motor symptoms, Parkinson disease",
author = "Abraham Lieberman and Narayanan Krishnamurthi",
year = "2013",
month = "2",
doi = "10.1007/s00702-012-0946-0",
language = "English (US)",
volume = "120",
pages = "347--348",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Is there room for non-dopaminergic treatment in Parkinson disease?

AU - Lieberman, Abraham

AU - Krishnamurthi, Narayanan

PY - 2013/2

Y1 - 2013/2

N2 - Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

AB - Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

KW - Levodopa

KW - Non-dopaminergic drugs

KW - Non-motor symptoms

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=84878398377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878398377&partnerID=8YFLogxK

U2 - 10.1007/s00702-012-0946-0

DO - 10.1007/s00702-012-0946-0

M3 - Article

C2 - 23242741

AN - SCOPUS:84878398377

VL - 120

SP - 347

EP - 348

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 2

ER -